Hint mode is switched on Switch off
For swift navigation between sections

Personalis
LEI 549300EZ2NYFK7H0US48

PDF download

Choose all Reset all
Download Cancel
Organization name
Personalis Inc.
Country name
USA
Country of registration
USA
Industry
Medical Services
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It was founded in 2011.

Awards

News

20/07/2026 Needham Downgrades Personalis (NASDAQ:PSNL) Following Tempus AI Acquisition News
20/07/2026 Personalis: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
20/07/2026 Personalis: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
13/03/2026 Personalis: Departure Of Directors Or Principal Officers; Election Of Directors; Appointment Of Principal Officers; Compensatory Arrangements Of Certain Officers
08/01/2026 Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300EZ2NYFK7H0US48
  • SIC
    8071 SERVICES-MEDICAL LABORATORIES
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001527753
  • EIN
    27-5411038
Registration is required to get access.